Home / Market News / $JNJ
benzinga Corporate Catalyst Impact 55/100 ● negative

RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $280

Oct 14, 2026, 1:38 PM UTC · Primary ticker $JNJ

RBC Capital analyst Trung Huynh maintained an Outperform rating on Johnson & Johnson but reduced the price target from $290 to $280. This indicates a slightly less optimistic outlook on the stock's future valuation, though the overall positive sentiment remains.

RBC Capital's analyst Trung Huynh reiterated an 'Outperform' rating for Johnson & Johnson, signaling continued confidence in the company's long-term prospects. However, the price target was lowered from $290 to $280. This adjustment suggests a recalibration of valuation expectations, possibly due to minor shifts in market conditions, company-specific outlook, or broader economic factors. For traders, this is a moderate signal; while the rating remains positive, the reduced price target could lead to short-term downward pressure or limit upside potential. Long-term investors might view this as a minor adjustment without altering their fundamental thesis on JNJ, given the maintained 'Outperform' rating.

$JNJ negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.